The present application relates to selective partial adenosine A1 receptor agonists of the formula (I) and their use for treating and/or preventing diseases and to their use for preparing medicaments for treating and/or preventing diseases, preferably for treating and/or preventing acute and/or chronic kidney disorders (primary disorder and secondary disorder) with and without concomitant acute and/or chronic heart disorders.